Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 2, 2023
Daily News
November 2, 2023
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- How Can Innovative Field Force Roles and Ways of Working Create More Impactful Engagement?
November 2, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- Shionogi, Apnimed to Launch Joint Venture to Develop Sleep Apnea Drugs
November 2, 2023
- Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
November 2, 2023
- MHLW to Consider Investigation on OTC Drug Abuse: Minister
November 2, 2023
- Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
- Mitsubishi Tanabe’s April-September Sales Up 8% on Radicava
November 2, 2023
- Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
November 2, 2023
- Otsuka Ups 2023 Full-Year Sales Forecast on Bullish Global Brands
November 2, 2023
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…